Education
About Us
Working with TipRanks
Follow Us
Nu Skin Enterprises (NUS)
NYSE:NUS
Top Page
Nu Skin
(NYSE:NUS)
Select Model
Select Model
Rating:61Neutral
Price Target:
$10.50
▲(0.86% Upside)
Nu Skin's overall stock score reflects a balance of positive valuation and strategic growth initiatives against the backdrop of declining revenue and cash flow. The company's strong performance in emerging markets and product innovation are promising, but operational challenges and market pressures remain significant risks.
Positive Factors
Emerging Market Growth
Strong growth in Latin America underscores Nu Skin's successful expansion strategy in emerging markets, providing a durable revenue stream.
Product Innovation
The launch of Prysm iO reflects Nu Skin's commitment to innovation, potentially driving long-term growth and market differentiation.
Improved Margins
Consistent margin improvement indicates effective cost management and product mix optimization, enhancing profitability sustainability.
Negative Factors
Declining Revenue
Declining revenue growth poses a challenge to Nu Skin's financial health, potentially impacting long-term business stability.
Free Cash Flow Decline
A decline in free cash flow generation limits Nu Skin's ability to invest in growth opportunities and maintain financial flexibility.
Challenges in North America
Ongoing difficulties in North America highlight regional vulnerabilities that could hinder overall company performance and growth.
Nu Skin (NUS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$503.59M
Dividend Yield2.39%
Average Volume (3M)405.10K
Price to Earnings (P/E)4.7
Beta (1Y)1.01
Revenue Growth-12.10%
EPS GrowthN/A
CountryUS
Employees3,100
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)0.34
Shares Outstanding48,750,076
10 Day Avg. Volume346,572
30 Day Avg. Volume405,101
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.53
Price to Sales (P/S)0.20
P/FCF Ratio4.88
Enterprise Value/Market Cap1.29
Enterprise Value/Revenue0.42
Enterprise Value/Gross Profit0.62
Enterprise Value/Ebitda3.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nu Skin Business Overview & Revenue Model
Company DescriptionNu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, LifePak nutritional supplements, ageLOC Meta nutritional supplements, and Beauty Focus Collagen+ skin care supplements, as well as other weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
How the Company Makes MoneyNu Skin generates revenue primarily through the sale of its personal care and nutritional products. The company employs a direct selling model, where independent distributors earn commissions on their sales and the sales made by their recruited team members. This multi-level marketing structure allows Nu Skin to expand its market reach while incentivizing distributors to promote and sell products. Key revenue streams include skincare products, dietary supplements, and wellness devices. Additionally, Nu Skin invests in technological advancements and maintains partnerships with research institutions, enhancing its product offerings and brand credibility, which further contribute to its earnings.
Nu Skin Earnings Call Summary
Earnings Call Date:Nov 06, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Feb 18, 2026
Earnings Call Sentiment Positive
The earnings call showed a positive outlook with strong growth in emerging markets and the launch of innovative products like Prysm iO. Despite challenges in North America and the impact of foreign currency, the company's strategic initiatives and financial improvements indicate a promising future.Q3-2025 Updates
Positive Updates
Strong Performance in Latin America
Latin America showed exceptional growth with a 53% year-over-year increase, highlighting the success of Nu Skin's emerging market strategy.
Sequential Growth in European and Asian Markets
Achieved sequential growth in Europe and Africa, South Korea, Southeast Asia Pacific, Hong Kong, and Taiwan, showing recovery and positive trends in these regions.
Launch of Prysm iO
Introduction of the Prysm iO wellness platform, with plans to place over 10,000 units in Q4, signaling a significant growth driver.
Improved Gross Margin
Gross margin improved to 70.5%, marking the fifth consecutive quarter of improvement, which was attributed to strategic portfolio optimization and product mix improvements.
Strong Financial Position
Closed the quarter with $252 million in cash, reduced total debt by $20 million, and maintained a positive net cash position.
Negative Updates
Challenges in North America
Continued challenges in the North American market due to macro environmental factors and changes in the business model.
Foreign Currency Headwinds
The company faced a 40 basis point headwind from foreign currency, impacting revenue.
Premium Beauty Under Pressure
Premium beauty continues to face challenges, affecting overall market performance.
Company Guidance
During the Q3 2025 earnings call, Nu Skin Enterprises reported revenue of $364 million, which was within their guidance range, and an EPS of $0.34, hitting the higher end of expectations. The company highlighted significant growth in Latin America, up 53% year-over-year, while North America faced ongoing challenges. Sequential growth was noted in Europe, Africa, South Korea, Southeast Asia Pacific, and Hong Kong and Taiwan. Nu Skin emphasized their strategic focus on launching the Prysm iO, an intelligent wellness platform, and expanding into the Indian market, with full-scale launches planned for 2026. The company maintained a strong financial position with a gross margin of 70.5% and operating margin of 5.9%. Looking ahead, they project Q4 revenue between $365 million to $400 million and EPS between $0.25 and $0.35, with a narrowed full-year revenue guidance of $1.48 billion to $1.51 billion, and full-year adjusted EPS expected between $1.25 and $1.35.Nu Skin Financial Statement Overview
Summary
Nu Skin's financial performance is mixed, with declining revenue and cash flow trends posing challenges. Despite improvements in profitability and leverage, operational inefficiencies need addressing to enhance financial health.Income Statement
Nu Skin's income statement shows a declining trend in revenue with a negative growth rate of -4.05% in the TTM. The gross profit margin remains relatively strong at 67.20%, but the net profit margin has improved to 7.02% from negative figures in previous years. However, EBIT margin is negative, indicating operational challenges. Overall, while profitability metrics show some improvement, the declining revenue trend is a concern.Balance Sheet
The balance sheet reflects a moderate debt-to-equity ratio of 0.36, indicating a manageable level of leverage. Return on equity has improved to 14.65% in the TTM, showing better utilization of equity. The equity ratio is stable, suggesting a balanced capital structure. While the company has reduced its debt, the overall asset base has slightly decreased, which could impact future growth.Cash Flow
Cash flow analysis reveals a decline in free cash flow growth by -8.99% in the TTM. The operating cash flow to net income ratio is 0.35, indicating moderate cash generation relative to net income. The free cash flow to net income ratio is 0.60, showing some efficiency in converting income to cash. Despite these metrics, the negative growth in free cash flow is a concern for future liquidity.| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.56B | 1.73B | 1.97B | 2.23B | 2.70B | 2.58B |
| Gross Profit | 1.05B | 1.18B | 1.36B | 1.59B | 2.02B | 1.92B |
| EBITDA | 191.82M | -78.83M | 202.98M | 174.97M | 368.48M | 331.56M |
| Net Income | 109.61M | -146.59M | 8.60M | 104.78M | 147.27M | 191.35M |
Balance Sheet | ||||||
| Total Assets | 1.42B | 1.47B | 1.81B | 1.82B | 1.91B | 1.96B |
| Cash, Cash Equivalents and Short-Term Investments | 253.00M | 197.99M | 267.82M | 278.51M | 354.81M | 423.90M |
| Total Debt | 291.43M | 478.23M | 607.33M | 520.52M | 503.79M | 500.38M |
| Total Liabilities | 624.61M | 817.46M | 984.50M | 923.67M | 993.71M | 1.06B |
| Stockholders Equity | 799.79M | 651.46M | 821.97M | 897.30M | 912.77M | 894.27M |
Cash Flow | ||||||
| Free Cash Flow | 53.35M | 70.16M | 60.15M | 49.01M | 72.97M | 315.32M |
| Operating Cash Flow | 89.45M | 111.74M | 118.64M | 108.06M | 141.58M | 379.14M |
| Investing Cash Flow | 166.80M | -37.96M | -134.50M | -67.08M | -88.73M | -79.43M |
| Financing Cash Flow | -227.53M | -133.18M | 10.73M | -99.50M | -104.70M | -245.17M |
Nu Skin Technical Analysis
Positive
10.41
Price Trends
10.04
Positive
10.78
Negative
9.20
Positive
Market Momentum
-0.03
Negative
56.28
Neutral
87.37
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUS, the sentiment is Positive. The current price of 10.41 is above the 20-day moving average (MA) of 10.13, above the 50-day MA of 10.04, and above the 200-day MA of 9.20, indicating a bullish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 56.28 is Neutral, neither overbought nor oversold. The STOCH value of 87.37 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NUS.
Nu Skin Risk Analysis
Nu Skin disclosed 12 risk factors in its most recent earnings report. Nu Skin reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nu Skin Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $5.13B | 60.99 | 8.77% | ― | 13.80% | -25.02% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | $503.59M | 4.75 | 14.55% | 2.39% | -12.10% | ― | |
58 Neutral | $826.39M | 34.11 | 1.62% | 3.51% | -1.34% | -73.59% | |
56 Neutral | $40.98B | -42.69 | -20.73% | 1.30% | -6.36% | -554.84% | |
51 Neutral | $198.90M | -7.06 | -18.73% | ― | -13.14% | 57.98% | |
49 Neutral | $2.79B | -6.86 | -9.96% | ― | -5.68% | -358.36% |
* Consumer Defensive Sector Average
NUS
Nu Skin
10.32
4.26
70.30%
EL
The Estée Lauder Companies
110.27
38.09
52.77%
COTY
Coty
3.12
-3.55
-53.22%
EPC
Edgewell Personal Care
17.69
-13.04
-42.43%
ELF
e.l.f. Beauty
86.05
-38.84
-31.10%
SKIN
Beauty Health
1.56
0.01
0.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.